XML 38 R27.htm IDEA: XBRL DOCUMENT v3.24.3
Long-Term Investments (Tables)
 9 Months Ended
Sep. 30, 2024
Long-Term Investments [Abstract]  
Schedule of Ownership Percentages of Each Investee The ownership percentages of each investee are listed as follows:
   Ownership percentage    
   September 30,   December 31,   Accounting
Name of investee  2024   2023   treatments
Braingenesis Biotechnology Co., Ltd.   0.17%   0.17%  Cost Method
Genepharm Biotech Corporation   0.67%   0.67%  Cost Method
BioHopeKing Corporation   5.90%   5.90%  Cost Method
ForSeeCon Corporation (see Note 10)   19.78%   -%   Cost Method
BioFirst Corporation (see Note 10)   18.68%   18.68%  Equity Method
OncoX BioPharma, Inc. (see Note 10)   24.97%   -%   Equity Method
Rgene Corporation (see Note 10)   26.65%   26.65%  Equity Method
(2) The extent the investee relies on the company for its business are summarized as follows:
Schedule of Extent the Investee Relies The extent the investee relies on the company for its business are summarized as follows:
Name of investee   The extent the investee relies on the Company for its business
Braingenesis Biotechnology Co., Ltd.   No specific business relationship
Genepharm Biotech Corporation   No specific business relationship
BioHopeKing Corporation   Collaborating with the Company to develop and commercialize drugs
ForSeeCon Corporation   Collaborating with the Company to develop and commercialize ophthalmic medical devices (referring to Note 4, Collaborative Agreements)
OncoX BioPharma, Inc.     Collaborating with the Company to develop and commercialize single-herb botanical drug for treatment of certain diseases (referring to Note 4, Collaborative Agreements)
BioFirst Corporation   Loaned from investee and provides research and development support service
Rgene Corporation   Collaborating with the Company to develop and commercialize drugs
BioLite Japan K.K.   Prepaid investment for a Joint Venture
(3) Long-term investment mainly consists of the following:
Schedule of Long-Term Investment Long-term investment mainly consists of the following:
   September 30,
2024		   December 31,
2023		 
   (Unaudited)     
Non-marketable Cost Method Investments, net        
Braingenesis Biotechnology Co., Ltd.  $6,948   $7,213 
Genepharm Biotech Corporation   21,213    22,021 
BioHopeKing Corporation   787,999    818,018 
ForSeeCon Corporation (See Note 4)   
-
    
-
 
Sub total   816,160    847,252 
Equity Method Investments, net          
BioFirst Corporation (a)   1,517,744    1,680,488 
Rgene Corporation (b)   
-
    
-
 
Total  $2,333,904   $2,527,740 
(a) BioFirst Corporation (the “BioFirst”):

The Company holds an equity interest in BioFirst Corporation, accounting for its equity interest using the equity method to accounts for its equity investment as prescribed in ASC 323, Investments-Equity Method and Joint Ventures (“ASC 323”). Equity method adjustments include the Company’s proportionate share of investee’s income or loss and other adjustments required by the equity method. As of September 30, 2024 and December 31, 2023, the Company owns 18.68% and 18.68% common stock shares of BioFirst, respectively. The Company made a prepayment for equity investment in BioFirst to purchase additional shares to be issued by BioFirst in the aggregate amount of $2,688,578, recorded as prepayment for long-term investments as of December 31, 2022. On July 19, 2023, the Company successfully completed the registration process for this investment. The initial prepayment was $1,895,556, which is a portion of the prepayment as of December 31, 2022, and was converted into 994,450 shares of BioFirst stock. As of September 30, 2024, the amount of prepayment for long-term investments in BioFirst is $1,124,842.

(b) Rgene Corporation (the “Rgene”)

Both Rgene and the Company are under common control by Dr. Tsung-Shann Jiang, the CEO and Chairman of the BioLite Inc. Since Dr. Tsung-Shann Jiang is able to exercise significant influence, but not control, over the Rgene, the Company determined to use the equity method to account for its equity investment as prescribed in ASC 323, Investments-Equity Method and Joint Ventures (“ASC 323”). Equity method adjustments include the Company’s proportionate share of investee’s income or loss and other adjustments required by the equity method. As of September 30, 2024 and December 31, 2023, the Company owns 26.65% and 26.65% Common Stock shares of Rgene, respectively.
Schedule of Components of Losses on Equity Investments The components of losses on equity investments for each period were as follows:
   Nine months Ended
September 30,		 
   2024   2023 
   (Unaudited) 
Share of equity method investee losses  $146,942   $     -